Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2293 - Real-World Survival Outcomes in Patients with Advanced Urothelial Cancer in Germany


10 Sep 2017


Poster display session


Cancers in Adolescents and Young Adults (AYA);  Bioethical Principles and GCP;  Urothelial Cancers


Günter Niegisch


Annals of Oncology (2017) 28 (suppl_5): v395-v402. 10.1093/annonc/mdx375


G. Niegisch1, H. Gerullis2, S. Lin3, J. Pavlova4, A. Gondos5, A. Rudolph5, G. Haas5, N. Hennies5, M.W. Kramer6

Author affiliations

  • 1 Department Of Urology, Heinrich-Heine-University Düsseldorf, 40225 - Düsseldorf/DE
  • 2 Clinic For Urology, University Clinic Oldenburg, Oldenburg/DE
  • 3 Real World Science, Genentech, Inc., South San Francisco/US
  • 4 Oncology, F. Hoffmann-La Roche AG - Switzerland, 4070 - Basel/CH
  • 5 Real World Insights, QuintilesIMS, Frankfurt/DE
  • 6 Clinic For Urology, University Clinic Schleswig-Holstein, Lübeck/DE


Abstract 2293


Contemporary data from the advanced urothelial cancer (UC) setting are scarce. Here, we describe treatment (tx) patterns and outcomes among > 350 patients (pts) in Germany.


Data were extracted from pt medical records from office-based urologists and urology clinics in Germany. Adult pts (age ≥ 18 y) diagnosed with T4b, N2-3 and/or M1 UC and received first-line (1L) or second-line (2L) palliative chemotherapy from 2009 to 2016 were included. The index date was the start date of first systemic therapy. We described tx patterns and clinical characteristics; Kaplan-Meier method assessed overall survival (OS). Cox regression adjusted for age, Eastern Cooperative Oncology Group performance status (ECOG PS) and liver metastases, stratified by hospital/office, compared tx.


Among 368 included pts, 356 and 107 received 1L and 2L tx, respectively. At the start of 1L therapy, mean age was 68 y, 73% of pts were male, 74% were current/ex-smokers and 63% had metastatic disease. In 1L, 75% of pts received dual-combination tx, most commonly gemcitabine + cisplatin (GemCis; 83%). In 2L, 74% received single-agent tx, most commonly vinflunine (66%). In 1L, 12-month OS was 60%, slightly higher with GemCis (65%) than with other tx (52%). No difference in OS by sex or smoking status was noted. Pts with and without renal impairment (creatinine clearance


Outcomes in advanced UC tx in pts in this large real-world data study are comparable with clinical trials. Despite frequent use of cisplatin-based 1L tx and vinflunine 2L tx, per recent guidelines, outcomes are generally still poor.

Clinical trial identification

Legal entity responsible for the study

F. Hoffman-La Roche Ltd.


F. Hofman-La Roche Ltd.


G. Niegisch: Research funding: 4SC AG Lecturer: Pfizer Pharma GmbH, Pierre Fabre Pharma GmbH, Roche Pharma AG Consulting or Advisory Role: Bristol-Myers Squibb, Roche Parma AG, IMS Health AG, medac GmbH Travel, Accommodations, Expense: Pfizer Pharma GmbH, Roche Pharma AG, Bristol-Myers Squibb. S-W. Lin: Receive salary and stocks from Genentech/Roche. J. Pavlova: Employee: Roche. A. Gondos, A. Rudolph, G. Haas: Employed by QuintilesIMS during the study. M.W. Kramer: Received honories for advisory board memberships and presentations from Roche, Pierre Fabre, Bristol-Myers Squibb, Novartis, Bayer, Astellas, Sanofi, Ipsen and Eisai. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.